Novel pathway for sudden cardiac death prevention.
Sudden cardiac death is one of the leading causes of death in the United States, accounting for an estimate 350,000 deaths each year. The US Congress passed a resolution in late September 2008 designating October as "National Sudden Cardiac Arrest Awareness Month." In an effort to raise awareness for preventing unnecessary deaths because of sudden cardiac death, the resolution "calls upon the people of the United States to observe this month with appropriate programs and activities." The response from our institute was to develop a novel pathway named ESCAPE-which is an evidence-based novel pathway for low Ejection fraction and Sudden Cardiac death Awareness and Prevention Eligibility. The main objective of this program is to demonstrate that implementing a simple novel pathway for primary prevention of sudden cardiac arrest leads to an increase in the number of patients with low ejection fraction (<or=35%) referred for implantable cardioverter defibrillators therapy. The key difference of our pathway compared with prior reported algorithms is that it is initiated at imaging laboratories. The registry will consist of consecutive patients presenting to our imaging laboratories (the echocardiography, the nuclear, and the cardiac catheterization laboratories). The ESCAPE pathway defines patients' management based upon 3 key parameters: left ventricular ejection function, heart failure functional class, and an evidence of a prior myocardial infarction or coronary artery disease. We hope that this new novel pathway will help to bridge the gap between the complex guidelines and the actual clinical practice and will help to save many lives.
Herzog
Eyal
E
Division of Cardiology-Cardiac Care Unit, St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York 10025, USA. Eherzog@chpnet.org
Aziz
Emad F
EF
Kukin
Marrick
M
Steinberg
Jonathan S
JS
Mittal
Suneet
S
D003324:Coronary Artery Disease / Q000150:complications / Q000175:diagnosis; D019091:Critical Pathways; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D012680:Sensitivity and Specificity; D013318:Stroke Volume / Q000502:physiology; D016019:Survival Analysis; D014481:United States